Eli Lilly Cuts Sales Outlook After Sluggish Growth for Incretin Drugs 0 14.01.2025 18:40 The Wall Street Journal Eli Lilly cut its outlook for fourth-quarter revenue citing sluggish growth in the market for incretin, which increases insulin levels. Moscow.media Частные объявления сегодня Rss.plus Все новости за 24 часа
